Management of Elevated Non-HDL Cholesterol

Understanding Non-HDL Cholesterol as a Treatment Target

Non-HDL cholesterol represents the total pool of all atherogenic lipoproteins, including LDL, VLDL, remnant lipoproteins, and lipoprotein(a), making it a powerful independent predictor of cardiovascular events, according to the American College of Cardiology 3, 4, 1
Non-HDL cholesterol becomes particularly valuable when triglycerides are ≥200 mg/dL, as it captures the risk from remnant lipoproteins that LDL-C alone misses, as stated by the American Heart Association 3, 5, 2

For high-risk patients, the American College of Cardiology recommends an LDL-C goal of <100 mg/dL and a non-HDL-C goal of <130 mg/dL 5, 1, 2
For intermediate-risk patients, the American College of Cardiology recommends an LDL-C goal of <130 mg/dL and a non-HDL-C goal of <160 mg/dL 3, 1
For lower-risk patients, the American College of Cardiology recommends an LDL-C goal of <160 mg/dL and a non-HDL-C goal of <190 mg/dL 3, 1

The American Heart Association recommends initiating therapeutic lifestyle changes, including reducing saturated fat to <7% of total calories and cholesterol to <200 mg/day, and eliminating all trans fatty acids 5, 2
The American College of Cardiology recommends initiating statin therapy simultaneously with lifestyle changes in high-risk patients, with a goal of reducing LDL-C by 30-40% or >50% if targeting LDL-C <70 mg/dL 1, 2
For patients with very high triglycerides (≥500 mg/dL), the American Diabetes Association recommends initiating fibrate or niacin therapy before LDL-lowering therapy, then treating LDL-C to goal after triglyceride reduction 5

The American College of Cardiology warns against substituting over-the-counter or dietary supplement niacin for prescription niacin, and recommends using prescription niacin only 5, 1
The American Heart Association recommends avoiding the combination of high-dose statin plus fibrate, as it significantly increases myopathy risk, and using lower statin doses with this combination 5
The American College of Cardiology recommends monitoring liver function and creatine kinase when using statins, and reassessing lipid panel 4-12 weeks after initiating or adjusting therapy 2